Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway*

Background: In ulcerative colitis (UC) butyrate metabolism is impaired due to a defect in the butyrate oxidation pathway and/or transport. In the present study we correlated butyrate uptake and oxidation to the gene expression of the butyrate transporter SLC16A1 and the enzymes involved in butyrate oxidation (ACSM3, ACADS, ECHS1, HSD17B10, and ACAT2) in UC and controls. Methods: Colonic mucosal biopsies were collected during endoscopy of 88 UC patients and 20 controls with normal colonoscopy. Butyrate uptake and oxidation was measured by incubating biopsies with 14C‐labeled Na‐butyrate. To assess gene expression, total RNA from biopsies was used for quantitative reverse‐transcription polymerase chain reaction (qRT‐PCR). In 20 UC patients, gene expression was reassessed after treatment with infliximab. Results: Butyrate uptake and oxidation were significantly decreased in UC versus controls (P < 0.001 for both). Butyrate oxidation remained significantly reduced in UC after correction for butyrate uptake (P < 0.001), suggesting that the butyrate oxidation pathway itself is also affected. Also, the mucosal gene expression of SLC16A1, ACSM3, ACADS, ECHS1, HSD17B10, and ACAT2 was significantly decreased in UC as compared with controls (P < 0.001 for all). In a subgroup of patients (n = 20), the gene expression was reassessed after infliximab therapy. In responders to therapy, a significant increase in gene expression was observed. Nevertheless, only ACSM3 mRNA levels returned to control values after therapy in the responders groups. Conclusions: The deficiency in the colonic butyrate metabolism in UC is initiated at the gene expression level and is the result of a decreased expression of SLC16A1 and enzymes in the &bgr;‐oxidation pathway of butyrate. (Inflamm Bowel Dis 2012;)

[1]  R. Place,et al.  HDAC inhibition prevents NF-κB activation by suppressing proteasome activity: Down-regulation of proteasome subunit expression stabilizes IκBα , 2005 .

[2]  P. Mortensen,et al.  Substrate utilization by intestinal mucosal tissue strips from patients with inflammatory bowel disease. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[3]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[4]  J. Doré,et al.  Low counts of Faecalibacterium prausnitzii in colitis microbiota , 2009, Inflammatory bowel diseases.

[5]  P. Rutgeerts,et al.  In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. , 1998, Gastroenterology.

[6]  C. M. Wood,et al.  Treatment of diversion colitis with short-chain-fatty acid irrigation. , 1989, The New England journal of medicine.

[7]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[8]  P. Rutgeerts,et al.  Pouchitis, Similar to Active Ulcerative Colitis, Is Associated with Impaired Butyrate Oxidation by Intestinal Mucosa , 2009, Inflammatory bowel diseases.

[9]  D. Jonkers,et al.  Review article: the role of butyrate on colonic function , 2007, Alimentary pharmacology & therapeutics.

[10]  P. Rutgeerts,et al.  Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β‐oxidation pathway , 2011, Alimentary pharmacology & therapeutics.

[11]  K. Nones,et al.  Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species , 2010, BMC Immunology.

[12]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[13]  O. P. Dinnick,et al.  UNSAFE ANÆSTHETIC SUPPLY SYSTEMS , 1975, The Lancet.

[14]  W. E. W. ROEDlGER.  Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man , 2006 .

[15]  J. Galmiche,et al.  Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. , 2000, Gut.

[16]  J. Weniger,et al.  Der Stickstoff-, Kohlenstoff- und Energiegehalt des Fleisches und der Wärmewert des Fettes verschiedener Nutztierarten , 1958 .

[17]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[18]  W. Roediger,et al.  THE COLONIC EPITHELIUM IN ULCERATIVE COLITIS: AN ENERGY-DEFICIENCY DISEASE? , 1980, The Lancet.

[19]  S. Asai,et al.  Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis , 2007, Scandinavian journal of gastroenterology.

[20]  Arnaud Bourreille,et al.  Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: A transport deficiency , 2010, Inflammatory bowel diseases.

[21]  Boyle,et al.  Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. , 1994, Gut.

[22]  B. Ramakrishna,et al.  Impairment of mitochondrial acetoacetyl CoA thiolase activity in the colonic mucosa of patients with ulcerative colitis , 2007, Gut.

[23]  W. Roediger.  Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. , 1980, Gut.

[24]  I. Finnie,et al.  Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. , 1993, Gut.

[25]  J. Hansen,et al.  Gene expression patterns in experimental colitis in IL‐10‐deficient mice , 2009, Inflammatory bowel diseases.

[26]  Patrick J. Lindsey,et al.  Butyrate-Induced Transcriptional Changes in Human Colonic Mucosa , 2009, PloS one.

[27]  S. Krishnan,et al.  Butyrate and glucose metabolism by colonocytes in experimental colitis in mice , 2000, Gut.

[28]  P. Rutgeerts,et al.  Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment , 2011, The American Journal of Gastroenterology.

[29]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[30]  I. Wilson,et al.  Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. , 2007, Journal of proteome research.

[31]  T. Layden,et al.  Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[32]  J. Fitzpatrick,et al.  Mucosal metabolism in ulcerative colitis and crohn's disease , 1998, Diseases of the colon and rectum.

[33]  Kristian Daly,et al.  Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. , 2007, Gastroenterology.

[34]  J. Saurin,et al.  Tumor Necrosis Factor &agr; Reduces Butyrate Oxidation In Vitro in Human Colonic Mucosa: A Link from Inflammatory Process to Mucosal Damage? , 2005, Inflammatory bowel diseases.

[35]  J. Postberg,et al.  Intestinal alpha‐defensin expression in pediatric inflammatory bowel disease1 , 2011, Inflammatory bowel diseases.

[36]  P. Mortensen,et al.  Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate , 1995, Digestive Diseases and Sciences.

[37]  S. Danese.  Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  J. Davie.  Inhibition of histone deacetylase activity by butyrate. , 2003, The Journal of nutrition.

[39]  R. Place,et al.  HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. , 2005, Biochemical pharmacology.

[40]  A. Light,et al.  Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. , 1996, Gut.

[41]  R. Macdermott,et al.  Increased Expression of Interleukin‐8 mRNA in Ulcerative Colitis and Crohn's Disease Mucosa and Epithelial Cells , 1995, Inflammatory bowel diseases.

[42]  I. Macdonald,et al.  In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis , 2000, Gut.

[43]  R. Caprilli,et al.  Fecal lactate and ulcerative colitis. , 1988, Gastroenterology.

[44]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[45]  M. Chapman,et al.  In vivo colonic butyrate metabolism and colonic permeability in extensive ulcerative colitis. , 1998, Gastroenterology.

[46]  J. Reimund,et al.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. , 1996, Gut.

[47]  Isabelle Cleynen,et al.  Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment , 2009, PloS one.

[48]  Penny A. Johnson,et al.  Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease , 2003, The Journal of pathology.

[49]  P. Mortensen,et al.  Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. , 1996, Scandinavian journal of gastroenterology. Supplement.